To determine how MIS416-mediated NOD2 and TLR9 signaling may modulate immune responses during MS, we used the EAE mouse model of MS to determine the effect of MIS416 treatment on the development of T cell-mediated autoimmune responses. Here, TLR9 is linked to myeloid sarcoma.